Automate Your Wheel Strategy on NVAX
With Tiblio's Option Bot, you can configure your own wheel strategy including NVAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVAX
- Rev/Share 7.7924
- Book/Share -0.4697
- PB -15.308
- Debt/Equity -3.0229
- CurrentRatio 2.0561
- ROIC 0.46
- MktCap 1164564300.0
- FreeCF/Share -1.2205
- PFCF -5.9248
- PE 2.4189
- Debt/Assets 0.1768
- DivYield 0
- ROE -1.1551
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVAX | BTIG Research | -- | Buy | -- | $19 | Feb. 28, 2025 |
News
Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Published: February 27, 2025 by: PRNewsWire
Sentiment: Neutral
Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohort Completed $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 million Advanced pipeline programs, based on proven and innovative technology platform Ended full year 2024 with over $1 billion in Cash and accounts receivables Provides 2025 financial guidance …
Read More
What's in Store for These 5 Biotech Stocks This Earnings Season?
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Read More
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the previous trading session.
Read More
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
GAITHERSBURG, Md. , Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m.
Read More
Novavax to Report Q4 Earnings: Here's What You Can Expect
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
Read More
Novavax (NVAX) Outperforms Broader Market: What You Need to Know
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day.
Read More
About Novavax, Inc. (NVAX)
- IPO Date 1995-12-05
- Website https://www.novavax.com
- Industry Biotechnology
- CEO Mr. John Charles Jacobs M.B.A.
- Employees 952